Arena Pharmaceuticals Company Description
Though not a football team, Arena Pharmaceuticals likes the end-around. The firm's CART technology discovers drugs without first identifying ligands, the molecules that bind to a drug's potential target and trigger a biological response. The technology mimics the behavior of ligands to identify chemical compounds that alter biological responses, facilitating faster drug discovery. Arena's focus is on treatments for metabolic, cardiovascular, and central nervous system diseases. Lead drug candidate lorcaserin could help obese people control body fat. Arena earns most of its revenues from R&D partnerships, including one with Ortho-McNeil Pharmaceutical to develop a treatment for type 2 diabetes.
View the Comprehensive Company Description for Arena Pharmaceuticals
The Company Description provides a historical perspective of Arena Pharmaceuticals's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Arena Pharmaceuticals's evolution in the marketplace.
